Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 14 | 2004 | 29 | 0.550 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2003 | 4 | 0.220 |
Why?
|
| Bone Marrow | 10 | 2001 | 79 | 0.200 |
Why?
|
| Apoptosis | 8 | 1999 | 177 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2004 | 182 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2001 | 46 | 0.130 |
Why?
|
| Interphase | 4 | 1990 | 5 | 0.110 |
Why?
|
| Thalidomide | 2 | 2001 | 4 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2011 | 19 | 0.090 |
Why?
|
| Cytokines | 4 | 2001 | 212 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2011 | 56 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 42 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 55 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 4 | 1999 | 9 | 0.080 |
Why?
|
| Biomarkers | 2 | 2011 | 554 | 0.080 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1988 | 4 | 0.080 |
Why?
|
| Tretinoin | 1 | 1988 | 13 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2000 | 222 | 0.080 |
Why?
|
| Humans | 22 | 2011 | 25692 | 0.060 |
Why?
|
| Cell Cycle | 3 | 1997 | 32 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 185 | 0.060 |
Why?
|
| Bromodeoxyuridine | 3 | 1997 | 10 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2011 | 568 | 0.060 |
Why?
|
| Pilot Projects | 4 | 2011 | 392 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 3 | 2001 | 86 | 0.050 |
Why?
|
| Male | 10 | 2011 | 13917 | 0.050 |
Why?
|
| Aged | 10 | 2011 | 8501 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 435 | 0.050 |
Why?
|
| Female | 9 | 2011 | 14273 | 0.050 |
Why?
|
| Cytarabine | 3 | 2001 | 11 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2001 | 47 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2001 | 56 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 124 | 0.040 |
Why?
|
| Anemia | 1 | 2001 | 88 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2011 | 4459 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 169 | 0.040 |
Why?
|
| Connective Tissue | 2 | 1996 | 22 | 0.040 |
Why?
|
| Palliative Care | 1 | 2000 | 99 | 0.040 |
Why?
|
| Cytogenetic Analysis | 3 | 2004 | 4 | 0.040 |
Why?
|
| Remission Induction | 3 | 2004 | 80 | 0.040 |
Why?
|
| Hematopoiesis | 4 | 2001 | 13 | 0.040 |
Why?
|
| Cell Division | 4 | 2001 | 79 | 0.040 |
Why?
|
| Idoxuridine | 1 | 1997 | 2 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 10 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 16 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1996 | 17 | 0.030 |
Why?
|
| Leukemia, Myeloid | 2 | 1995 | 4 | 0.030 |
Why?
|
| Middle Aged | 7 | 2011 | 8403 | 0.030 |
Why?
|
| DNA | 3 | 1997 | 95 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2004 | 3231 | 0.030 |
Why?
|
| Macrophages | 3 | 2001 | 97 | 0.030 |
Why?
|
| Adult | 5 | 2011 | 7336 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 1992 | 110 | 0.030 |
Why?
|
| Phenotype | 2 | 2011 | 292 | 0.030 |
Why?
|
| Time Factors | 2 | 2001 | 1336 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2001 | 72 | 0.020 |
Why?
|
| Mitoxantrone | 2 | 2001 | 4 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 48 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2001 | 12 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 126 | 0.020 |
Why?
|
| Amifostine | 2 | 2000 | 3 | 0.020 |
Why?
|
| Monosomy | 1 | 1990 | 1 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1990 | 3 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 14 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 116 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2011 | 88 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2001 | 532 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 170 | 0.020 |
Why?
|
| Cell Lineage | 2 | 2001 | 22 | 0.020 |
Why?
|
| Antigens, CD34 | 2 | 2001 | 12 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1989 | 9 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 351 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 37 | 0.020 |
Why?
|
| Nucleoproteins | 1 | 1988 | 2 | 0.020 |
Why?
|
| Superoxides | 1 | 1988 | 21 | 0.020 |
Why?
|
| Disease Progression | 2 | 2004 | 664 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1988 | 127 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 618 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 869 | 0.020 |
Why?
|
| DNA Fragmentation | 2 | 1996 | 5 | 0.020 |
Why?
|
| DNA Replication | 2 | 1996 | 10 | 0.020 |
Why?
|
| S Phase | 2 | 1999 | 10 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 1996 | 48 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 1077 | 0.020 |
Why?
|
| Anemia, Refractory | 1 | 2004 | 1 | 0.010 |
Why?
|
| Pancytopenia | 1 | 2004 | 3 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 9 | 0.010 |
Why?
|
| Infliximab | 1 | 2004 | 15 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 2224 | 0.010 |
Why?
|
| Acute Disease | 2 | 1995 | 187 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 148 | 0.010 |
Why?
|
| Lymphokines | 1 | 2001 | 7 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 12 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 14 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2001 | 8 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 8 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2001 | 27 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2001 | 12 | 0.010 |
Why?
|
| Adipocytes | 1 | 2001 | 20 | 0.010 |
Why?
|
| Endothelium | 1 | 2001 | 12 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 61 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2001 | 31 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2001 | 13 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2001 | 55 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2001 | 28 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 68 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 152 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 341 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2000 | 3 | 0.010 |
Why?
|
| Anorexia | 1 | 2000 | 3 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 2000 | 6 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 10 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2000 | 9 | 0.010 |
Why?
|
| Hypotension | 1 | 2000 | 23 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 30 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 34 | 0.010 |
Why?
|
| Karyotyping | 1 | 1999 | 8 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 14 | 0.010 |
Why?
|
| Age Factors | 1 | 2001 | 716 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 739 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1996 | 8 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 6 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 14 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1996 | 22 | 0.010 |
Why?
|
| Caspase 1 | 1 | 1996 | 13 | 0.010 |
Why?
|
| Leukemia | 1 | 1996 | 4 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 33 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2001 | 1781 | 0.010 |
Why?
|
| Biopsy | 1 | 1995 | 199 | 0.010 |
Why?
|
| Models, Biological | 1 | 1996 | 311 | 0.010 |
Why?
|
| Adolescent | 1 | 1999 | 2076 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 8 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 18 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1992 | 325 | 0.010 |
Why?
|
| Metaphase | 1 | 1990 | 2 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 6 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1990 | 26 | 0.010 |
Why?
|
| Regeneration | 1 | 1989 | 19 | 0.000 |
Why?
|